Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.
Leukemia. 2019 Jul;33(7):1650-1662. doi: 10.1038/s41375-019-0381-4. Epub 2019 Jan 29.
Leukemia. 2019.
PMID: 30696950
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
Reiff SD, Muhowski EM, Guinn D, Lehman A, Fabian CA, Cheney C, Mantel R, Smith L, Johnson AJ, Young WB, Johnson AR, Liu L, Byrd JC, Woyach JA.
Reiff SD, et al. Among authors: muhowski em.
Blood. 2018 Sep 6;132(10):1039-1049. doi: 10.1182/blood-2017-10-809020. Epub 2018 Jul 17.
Blood. 2018.
PMID: 30018078
Free PMC article.
Item in Clipboard
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, Goettl VM, Tran M, Harrington BK, Rogers KA, Awan FT, Maddocks K, Andritsos L, Lehman AM, Sampath D, Lapalombella R, Eathiraj S, Abbadessa G, Schwartz B, Johnson AJ, Byrd JC, Woyach JA.
Reiff SD, et al. Among authors: muhowski em.
Cancer Discov. 2018 Oct;8(10):1300-1315. doi: 10.1158/2159-8290.CD-17-1409. Epub 2018 Aug 9.
Cancer Discov. 2018.
PMID: 30093506
Free PMC article.
Item in Clipboard
Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition.
Eisenmann ED, Fu Q, Muhowski EM, Jin Y, Uddin ME, Garrison DA, Weber RH, Woyach J, Byrd JC, Sparreboom A, Baker SD.
Eisenmann ED, et al. Among authors: muhowski em.
Cancer Res Commun. 2021 Nov;1(2):79-89. doi: 10.1158/2767-9764.crc-21-0076. Epub 2021 Nov 9.
Cancer Res Commun. 2021.
PMID: 34950932
Free PMC article.
Item in Clipboard
Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.
Jain N, Singh S, Laliotis G, Hart A, Muhowski E, Kupcova K, Chrbolkova T, Khashab T, Chowdhury SM, Sircar A, Shirazi F, Singh RK, Alinari L, Zhu J, Havranek O, Tsichlis P, Woyach J, Baiocchi R, Samaniego F, Sehgal L.
Jain N, et al.
Blood Adv. 2020 Sep 22;4(18):4382-4392. doi: 10.1182/bloodadvances.2020001685.
Blood Adv. 2020.
PMID: 32926124
Free PMC article.
Item in Clipboard
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
Woyach JA, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, Eathiraj S, Reiff SD, Muhowski EM, Granlund L, Szuszkiewicz L, Wang W, Schwartz B, Ghori R, Farooqui MZH, Byrd JC.
Woyach JA, et al. Among authors: muhowski em.
Cancer Discov. 2024 Jan 12;14(1):66-75. doi: 10.1158/2159-8290.CD-23-0670.
Cancer Discov. 2024.
PMID: 37930156
Clinical Trial.
Item in Clipboard
Dual TCR-Expressing T Cells in Cancer: How Single-Cell Technologies Enable New Investigation.
Muhowski EM, Rogers LM.
Muhowski EM, et al.
Immunohorizons. 2023 May 1;7(5):299-306. doi: 10.4049/immunohorizons.2200062.
Immunohorizons. 2023.
PMID: 37129560
Free PMC article.
Item in Clipboard
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia.
Muhowski EM, Ravikrishnan J, Gordon B, Yu L, Misra S, Walker B, Eathiraj S, Sampath D, Rogers KA, Byrd JC, Woyach JA.
Muhowski EM, et al.
J Hematol Oncol. 2022 Nov 15;15(1):166. doi: 10.1186/s13045-022-01386-1.
J Hematol Oncol. 2022.
PMID: 36380319
Free PMC article.
Item in Clipboard
Cite
Cite